JPMorgan Upgrades The Medicines Company (MDCO) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Medicines Co. (MDCO) Reports Meeting Endpoints in SOLO-1 Phase 3
December 20, 2012 7:34 AM ESTThe Medicines Company (Nasdaq: MDCO) announced results for its SOLO-1 Phase 3 clinical trial of oritavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
All protocol-specified primary and secondary efficacy endpoints of the SOLO-1 trial were met. Oritavancin was shown to be non-inferior to vancomycin in the efficacy analyses for the early... More
